Literature DB >> 16132996

Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.

Silke Lassmann1, Michael Hennig, Robert Rosenberg, Jörg Nährig, Joachim Schreglmann, Friedemann Krause, Manuela Poignee-Heger, Hjalmar Nekarda, Heinz Höfler, Martin Werner.   

Abstract

AIM: Evaluation of thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), and thymidylate synthase (TS) mRNA levels in formalin-fixed, and paraffin-embedded tissues of patients with colorectal cancer and their prognostic and/or predictive value.
MATERIALS AND METHODS: Total RNA was isolated from microdissected, formalin-fixed, and paraffin-embedded tissues (controls and tumor) and subjected to quantitative RT-PCR (QRT-PCR) in the LightCycler system. Resulting mRNA levels correlated to tumor histology (n=102) and the clinical follow-up in patients treated by resection alone (n=40) and by resection plus adjuvant 5-FU-based chemotherapy (n=52).
RESULTS: Correlation to histopathological parameters revealed a significant association between tumor stage and the TP mRNA level (T and N category and UICC) as well as the TP:DPD (T and N category and UICC) and TS:DPD (T category) ratio. In addition, tumor differentiation was correlated to the TS mRNA level and the TS:DPD ratio. Finally, the TS:DPD ratio was a prognostic marker for overall survival in patients receiving resection alone (p=0.032). Moreover, a high TP:DPD ratio (>8.1; p=0.002) and, marginally, low DPD (<8.2; p=0.05) mRNA levels significantly correlated to disease-free survival.
CONCLUSION: We present a novel, standardized approach for TP, DPD, and TS mRNA quantification in archival tissue specimens and applied this to a large series of primary colorectal tumors. Correlations to histopathological parameters and clinical follow-up revealed an association of TP, DPD and TS mRNA expression patterns with tumor stage and suggested new prognostic and predictive markers for patients with colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132996     DOI: 10.1007/s00384-005-0767-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  49 in total

1.  Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.

Authors:  Carmen J Allegra; Allyson L Parr; Lester E Wold; Michelle R Mahoney; Daniel J Sargent; Patrick Johnston; Pam Klein; Katie Behan; Michael J O'Connell; Ralph Levitt; John W Kugler; Maria Tria Tirona; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

2.  Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method.

Authors:  T Takenoue; H Nagawa; K Matsuda; S Fujii; M E Nita; K Hatano; J Kitayama; T Tsuruo; T Muto
Journal:  Ann Surg Oncol       Date:  2000-04       Impact factor: 5.344

3.  Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.

Authors:  W Wang; S Marsh; J Cassidy; H L McLeod
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

4.  Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.

Authors:  Y Araki; H Isomoto; K Shirouzu
Journal:  Kurume Med J       Date:  2001

5.  Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.

Authors:  M R Johnson; A Hageboutros; K Wang; L High; J B Smith; R B Diasio
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

6.  Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK)

Authors: 
Journal:  Lancet       Date:  1995-02-11       Impact factor: 79.321

7.  Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study.

Authors:  S B Fox; A Moghaddam; M Westwood; H Turley; R Bicknell; K C Gatter; A L Harris
Journal:  J Pathol       Date:  1995-06       Impact factor: 7.996

8.  Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.

Authors:  M P Findlay; D Cunningham; G Morgan; S Clinton; A Hardcastle; G W Aherne
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.

Authors:  B Iacopetta; F Grieu; D Joseph; H Elsaleh
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

10.  Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.

Authors:  A Paradiso; G Simone; S Petroni; B Leone; C Vallejo; J Lacava; A Romero; M Machiavelli; M De Lena; C J Allegra; P G Johnston
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  17 in total

Review 1.  The Prognostic and Predictive Value of Dihydropyrimidine Dehydrogenase-Related Indicators in Clinical Outcomes of Chemotherapy in Colorectal Cancer Patients: a Systematic Review and Meta-Analysis.

Authors:  Xiaojun Sun; Shilei Guo
Journal:  Pathol Oncol Res       Date:  2018-12-05       Impact factor: 3.201

2.  Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.

Authors:  Yuji Morine; Mitsuo Shimada; Tohru Utsunomiya; Satoru Imura; Tetsuya Ikemoto; Jun Hanaka; Mami Kanamoto; Nobuhiro Kurita; Hidenori Miyake
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

3.  Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma.

Authors:  Shuichi Iwahashi; Mitsuo Shimada; Tohru Utsunomiya; Yuji Morine; Satoru Imura; Tetsuya Ikemoto; Hiroki Mori; Jun Hanaoka
Journal:  Surg Today       Date:  2012-01-24       Impact factor: 2.549

4.  Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.

Authors:  Marisa Donada; Serena Bonin; Ermanno Nardon; Alessandro De Pellegrin; Giuliana Decorti; Giorgio Stanta
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-13       Impact factor: 4.553

5.  Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.

Authors:  Naruji Kugimiya; Eijiro Harada; Yuki Suehiro; Atsushi Suga; Yoshihiro Takemoto; Kimikazu Hamano
Journal:  Oncol Lett       Date:  2019-03-21       Impact factor: 2.967

Review 6.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 7.  FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.

Authors:  Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Pavel Soucek
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

8.  STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation.

Authors:  Silke Lassmann; Ingrid Schuster; Axel Walch; Heike Göbel; Uta Jütting; Frank Makowiec; Ulrich Hopt; Martin Werner
Journal:  J Clin Pathol       Date:  2007-02       Impact factor: 3.411

9.  Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.

Authors:  Kohei Shigeta; Yoshiyuki Ishii; Hirotoshi Hasegawa; Koji Okabayashi; Yuko Kitagawa
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

10.  Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes.

Authors:  J P Burke; J H M Prehn; E O'Connell; I S Reynolds; M Salvucci; D A McNamara
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.